Fifty 1 Labs, Inc. and All-In-Extracts Announce
Joint Venture to Develop and Release New Testosterone Boosting
Supplement
Melbourne, FL --
August 5, 2024 -- InvestorsHub NewsWire -- Fifty 1 Labs,
Inc. (OTCPK:
CAFI), a holding company that operates in the sports
supplement, fitness equipment, and health and wellness industries,
and All-In-Extracts, a wholly owned subsidiary of Royal Biotek
Enterprises (OTCPK:
BLEG) and a renowned provider of high-quality botanical
extracts, are excited to announce a strategic joint venture to
develop and release a groundbreaking testosterone-boosting
supplement under Fifty 1 Labs wholly owned subsidiary, 51 Labs,
LLC. Clinical trials for this innovative product are set to begin
promptly.
This joint venture combines
the scientific research and advanced extraction techniques from
both companies to create a product aimed at supporting natural
testosterone production and enhancing overall well-being for men
and women.
Fifty 1 Labs' expertise in
supplement formulation and All-In-Extracts' superior botanical
extraction methods will be combined to develop a high-quality,
effective product. The synergy between these two industry leaders
promises a product that is both scientifically robust and naturally
potent.
The testosterone-boosting
supplement will feature a unique blend of natural ingredients known
for their potential to enhance testosterone levels and promote
vitality. These ingredients have been carefully selected based on
extensive research and clinical evidence supporting their
efficacy.
Clinical trials are set to
begin promptly to ensure the safety, efficacy, and quality of the
product. These trials will be conducted under rigorous scientific
protocols, with results expected to guide the final formulation and
dosage. This step underscores the commitment of both companies to
delivering a product that consumers can trust.
The new
testosterone-boosting supplement aims to address common issues
faced by men and women, such as low energy levels, reduced muscle
mass, and diminished libido. By supporting natural testosterone
production, the product is expected to improve overall health and
vitality, helping men and women to achieve a better quality of
life.
Pending successful clinical
trials, the new product is slated for market release in Q4 2024,
with an initial launch in the United States followed by
international expansion. The companies are also planning an
extensive marketing campaign to educate consumers about the
benefits of the new product.
"We are thrilled to
collaborate with All-In-Extracts on this innovative project," said
Robert Clark, CEO of Fifty 1 Labs, Inc. "Starting clinical trials
promptly demonstrates our commitment to bringing a safe, effective,
and high-quality product to the market. This joint venture allows
us to leverage our combined expertise and resources to create
something truly remarkable."
Matthew Grisham, CEO of
All-In-Extracts, added, "This joint venture reflects our shared
dedication to natural wellness and scientific excellence. We are
confident that our combined efforts will result in a product that
will significantly benefit the health of men and women. Our
commitment to quality and transparency ensures that consumers can
trust our product to deliver real results."
The testosterone-boosting
supplement aims to meet the needs of men and women seeking to
improve their energy, performance, and overall health through
natural means. Both companies are dedicated to transparency,
safety, and customer satisfaction, ensuring that the new product
will meet the highest standards.
About Fifty 1 Labs,
Inc. Fifty 1 Labs, Inc. (Ticker symbol: CAFI), a publicly
traded entity, is currently undergoing a name and symbol transition
to become Fifty 1 Labs, Inc. This transformation is accompanied by
the company's ownership of three distinct subsidiaries entrenched
within the domains of sports supplementation, fitness apparatus,
and holistic well-being. These subsidiaries include 51, LLC, a
pioneer in the development of innovative health and wellness
supplements. With a focus on science-backed formulations and
premium ingredients, 51 Labs is committed to helping individuals
achieve optimal health and well-being. The company's portfolio
includes a range of products designed to address various health
concerns, from cognitive function to physical performance: The
Quickness, the proud holder of a patent for pioneering athletic
training equipment meticulously crafted to enhance linebacker
development; Drago Knives, LLC, a cutting edge knife throwing
company with a patented style of throwing knives; and Astound NMN,
a beacon of excellence within the anti-aging sector, heralding the
era of DNA reparation through its premium supplements. Guided by an
unwavering commitment, Fifty 1 Labs, Inc. remains at the forefront
of innovation, consistently presenting avant-garde solutions
infused with state-of-the-art technology, poised to empower
individuals in their pursuit of fitness and holistic health
aspirations. Additionally, Fifty 1 Labs, Inc. remains actively
engaged in pursuing strategic acquisitions aimed at fortifying its
portfolio by incorporating profit-generating enterprises into its
fold.
About
All-In-Extracts All-In-Extracts, a wholly owned subsidiary
of Royal Biotek Enterprises (Ticker Symbol: BLEG) is a leading
provider of high-quality botanical extracts. Utilizing cutting-edge
extraction methods and rigorous quality control processes,
All-In-Extracts delivers potent and pure extracts that serve as the
foundation for numerous health and wellness products. The company's
dedication to sustainability and ethical sourcing ensures that
their products are not only effective but also environmentally
responsible.
Media
Contacts:
Fifty 1 Labs,
Inc.
Jonathan Werlang
Vice President
Email: ir@fifty1labs.com
Phone: (877) 814-4188
All-In-Extracts
Matthew Grisham
CEO
Email: info@starhillhemp.com
Phone: (987) 654-3210
For further information,
please visit Fifty 1 Labs'
website or All-In-Extracts'
website.
###
For further information,
please contact: Jonathan Werlang (877) 814-4188
Safe Harbor Statement: The
information provided in this release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Identifiable by words such as "may," "will,"
"should," "plans," "expects," "anticipates," "continue,"
"estimate," "project," "intend," and similar expressions, these
statements may also be made in written or oral form in the
company's filings with the U.S. Securities and Exchange Commission,
press releases, other written materials, or in oral statements made
by its officers, directors, or employees to third parties. There
can be no assurance that such statements will prove to be accurate.
The company cautions that these forward-looking statements are
further qualified by other factors including, but not limited to,
those set forth in the company's Registration Statement on Form
S-1. Forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from those
projected or anticipated. These risks and uncertainties include,
but are not limited to, general economic and business conditions,
effects of continued geopolitical unrest and regional conflicts,
competition, changes in technology and methods of marketing, delays
in completing various engineering and manufacturing programs,
changes in customer order patterns, changes in product mix,
continued success in technological advances and delivering
technological innovations, shortages in components, production
delays due to performance quality issues with outsourced
components, and various other factors beyond the company's control.
The company does not undertake any obligation to update publicly or
to revise any statements in this release, whether as a result of
new information, future events, or otherwise.
Branded Legacy (PK) (USOTC:BLEG)
Historical Stock Chart
From Oct 2024 to Nov 2024
Branded Legacy (PK) (USOTC:BLEG)
Historical Stock Chart
From Nov 2023 to Nov 2024
